Aspirin in Reducing Events in the Elderly (ASPREE)

Short Study Name (acronym): ASPREE

Long Name: Aspirin in Reducing Events in the Elderly

Investigators (list PI first):  Jeff Williamson, MD

Funding Agency: National Institute of Aging

Funding Dates: 2011 - 2015

Research questions or aims: ASPREE is a double-blind, randomized, placebo-controlled primary prevention trial designed to assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the duration of disability-free life in healthy participants aged 70 years and above.  The study will examine whether the potential benefits of low dose aspirin (particularly the prevention of heart disease, stroke, certain cancers and dementia) outweigh the risks (particularly severe gastrointestinal bleeding and hemorrhagic stroke) in this age group.

Target population: Men and Women 70 years of age and older who are in good general health

Target # to enroll:

 

Target Dates of enrollment:

Types of assessments and questionnaires:

Study Website (if applicable): www.aspree.org

Project Manager Contact Info: Patricia Wittmer
                                                         336-713-8243 
                                                         pwittmer@wakeahealth.edu

Last Updated: 08-21-2015
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.